A 3-year follow-up of women with endometriosis and pelvic pain users of the levonorgestrel-releasing intrauterine system

Petta, Carlos Alberto; Ferriani, Rui Alberto; Abrão, Maurício Simões; Hassan, Daniela Fink; Silva, Júlio C. Rosa e; Podgaec, Silvio; Bahamondes, Luís

doi:10.1016/j.ejogrb.2008.12.012

Cited by 27 publications

(14 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In one study randomizing women to either LNG-20 IUD or GnRHa, both treatments were found to be effective in controlling pelvic pain at 6 months,69 however, those randomized to LNG-20 IUD had a continuation rate of 59% at 36 months, and 82% of these women reported a lower pain score compared to the GnRHa group 72. A double-blind study comparing postoperative LNG-20 IUD to expectant management showed decreased dysmenorrhea in the LNG-20 IUD group, and longer time to pain recurrence in this group compared to expectant management 71.…”

Section: Noncontraceptive Benefits Of Iudsmentioning

confidence: 99%

Understanding benefits and addressing misperceptions and barriers to intrauterine device access among populations in the United States

Yoost¹

2014

PPA

View full text Add to dashboard Cite

Three intrauterine devices (IUDs), one copper and two containing the progestin levonorgestrel, are available for use in the United States. IUDs offer higher rates of contraceptive efficacy than nonlong-acting methods, and several studies have demonstrated higher satisfaction rates and continuation rates of any birth control method. This efficacy is not affected by age or parity. The safety of IUDs is well studied, and the risks of pelvic inflammatory disease, perforation, expulsion, and ectopic pregnancy are all of very low incidence. Noncontraceptive benefits include decreased menstrual blood loss, improved dysmenorrhea, improved pelvic pain associated with endometriosis, and protection of the endometrium from hyperplasia. The use of IUDs is accepted in patients with multiple medical problems who may have contraindications to other birth control methods. Yet despite well-published data, concerns and misperceptions still persist, especially among younger populations and nulliparous women. Medical governing bodies advocate for use of IUDs in these populations, as safety and efficacy is unchanged, and IUDs have been shown to decrease unintended pregnancies. Dispersion of accurate information among patients and practitioners is needed to further increase the acceptability and use of IUDs.

show abstract

Section: Noncontraceptive Benefits Of Iudsmentioning

confidence: 99%

Understanding benefits and addressing misperceptions and barriers to intrauterine device access among populations in the United States

Yoost¹

2014

PPA

View full text Add to dashboard Cite

show abstract

“…The effectiveness of a 6-month therapy with LNG-IUS or GnRH agonists to treat endometriosis-related chronic pelvic pain was compared in a number of randomized trials (182)(183)(184)(185)(186). In one study of 40 patients who had persistent pain after conservative laparoscopy, the VAS score did not improve, and patient satisfaction was lower in the LNG-IUStreated group (186).…”

Section: Contraceptive Methodsmentioning

confidence: 99%

Pharmacologic therapies in endometriosis: a systematic review

Soares¹,

Martínez-Varea

Hidalgo-Mora

et al. 2012

Fertility and Sterility

138

View full text Add to dashboard Cite

“…The role of the LNG-IUS in management of this common and debilitating disorder has been evaluated by multiple studies. 5,[23][24][25] A pilot study examined the role of LNG-IUS as a postoperative adjunct to surgical ablation for endometriosis. 26 When compared with expectant management, the LNG-IUS recipients had a reduced rate of recurrence of pelvic pain (2/20 compared with 9/20) and an increased rate of satisfaction (15/20 compared with 10/20).…”

Section: Endometriosis and The Levonorgestrel Intrauterine Systemmentioning

confidence: 99%

“…26 Similarly, a randomized controlled trial comparing LNG-IUS to medical therapy with a GnRHa had promising results. 25 Eighty-two women with surgically confirmed endometriosis were randomized to LNG-IUS or GnRHa and, using visual analog scores (VAS), pain and bleeding patterns were assessed at baseline and at 6-month intervals. At 36 months, 59% of women were still using the LNG-IUS and 82% of these users reported a lower VAS score compared with GnRHa.…”

Section: Endometriosis and The Levonorgestrel Intrauterine Systemmentioning

confidence: 99%

Non-contraceptive applications of the levonorgestrel intrauterine system

Rodríguez¹,

Darney²

2010

IJWH

View full text Add to dashboard Cite

Intrauterine progestins have many important current and potential gynecologic applications. This article describes the evidence for use of intrauterine progestin for common gynecologic conditions beyond its important role in contraception. The pharmacology of and selection criteria for use of the levonorgestrel intrauterine device is discussed, and the evidence for use of intrauterine progestin delivery for menorrhagia, endometriosis management, uterine fibroids, adenomyosis and endometrial hyperplasia is reviewed.

show abstract

A 3-year follow-up of women with endometriosis and pelvic pain users of the levonorgestrel-releasing intrauterine system

Cited by 27 publications

References 6 publications

Understanding benefits and addressing misperceptions and barriers to intrauterine device access among populations in the United States

Understanding benefits and addressing misperceptions and barriers to intrauterine device access among populations in the United States

Pharmacologic therapies in endometriosis: a systematic review

Non-contraceptive applications of the levonorgestrel intrauterine system

Contact Info

Product

Resources

About